These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

608 related articles for article (PubMed ID: 20570559)

  • 21. Double-blind, placebo-controlled, randomized phase 2 study of the proapoptotic agent AT-101 plus docetaxel, in second-line non-small cell lung cancer.
    Ready N; Karaseva NA; Orlov SV; Luft AV; Popovych O; Holmlund JT; Wood BA; Leopold L
    J Thorac Oncol; 2011 Apr; 6(4):781-5. PubMed ID: 21289522
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial.
    Leboulleux S; Bastholt L; Krause T; de la Fouchardiere C; Tennvall J; Awada A; Gómez JM; Bonichon F; Leenhardt L; Soufflet C; Licour M; Schlumberger MJ
    Lancet Oncol; 2012 Sep; 13(9):897-905. PubMed ID: 22898678
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A randomized, double-blind, placebo-controlled phase II study of vandetanib plus docetaxel/prednisolone in patients with hormone-refractory prostate cancer.
    Horti J; Widmark A; Stenzl A; Federico MH; Abratt RP; Sanders N; Pover GM; Bodrogi I
    Cancer Biother Radiopharm; 2009 Apr; 24(2):175-80. PubMed ID: 19409038
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Vandetanib Versus placebo in patients with advanced non-small-cell lung cancer after prior therapy with an epidermal growth factor receptor tyrosine kinase inhibitor: a randomized, double-blind phase III trial (ZEPHYR).
    Lee JS; Hirsh V; Park K; Qin S; Blajman CR; Perng RP; Chen YM; Emerson L; Langmuir P; Manegold C
    J Clin Oncol; 2012 Apr; 30(10):1114-21. PubMed ID: 22370318
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nedaplatin plus docetaxel versus cisplatin plus docetaxel for advanced or relapsed squamous cell carcinoma of the lung (WJOG5208L): a randomised, open-label, phase 3 trial.
    Shukuya T; Yamanaka T; Seto T; Daga H; Goto K; Saka H; Sugawara S; Takahashi T; Yokota S; Kaneda H; Kawaguchi T; Nagase S; Oguri T; Iwamoto Y; Nishimura T; Hattori Y; Nakagawa K; Nakanishi Y; Yamamoto N;
    Lancet Oncol; 2015 Dec; 16(16):1630-8. PubMed ID: 26522337
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Vandetanib plus chemotherapy for induction followed by vandetanib or placebo as maintenance for patients with advanced non-small-cell lung cancer: a randomized phase 2 PrECOG study (PrE0501).
    Aisner J; Manola JB; Dakhil SR; Stella PJ; Sovak MA; Schiller JH
    J Thorac Oncol; 2013 Aug; 8(8):1075-83. PubMed ID: 23689430
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial.
    Wu YL; Zhou C; Hu CP; Feng J; Lu S; Huang Y; Li W; Hou M; Shi JH; Lee KY; Xu CR; Massey D; Kim M; Shi Y; Geater SL
    Lancet Oncol; 2014 Feb; 15(2):213-22. PubMed ID: 24439929
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer.
    Heymach JV; Paz-Ares L; De Braud F; Sebastian M; Stewart DJ; Eberhardt WE; Ranade AA; Cohen G; Trigo JM; Sandler AB; Bonomi PD; Herbst RS; Krebs AD; Vasselli J; Johnson BE
    J Clin Oncol; 2008 Nov; 26(33):5407-15. PubMed ID: 18936474
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase III trial of vandetanib compared with erlotinib in patients with previously treated advanced non-small-cell lung cancer.
    Natale RB; Thongprasert S; Greco FA; Thomas M; Tsai CM; Sunpaweravong P; Ferry D; Mulatero C; Whorf R; Thompson J; Barlesi F; Langmuir P; Gogov S; Rowbottom JA; Goss GD
    J Clin Oncol; 2011 Mar; 29(8):1059-66. PubMed ID: 21282542
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Docetaxel or pemetrexed with or without cetuximab in recurrent or progressive non-small-cell lung cancer after platinum-based therapy: a phase 3, open-label, randomised trial.
    Kim ES; Neubauer M; Cohn A; Schwartzberg L; Garbo L; Caton J; Robert F; Reynolds C; Katz T; Chittoor S; Simms L; Saxman S
    Lancet Oncol; 2013 Dec; 14(13):1326-36. PubMed ID: 24231627
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sintilimab plus chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer with disease progression after EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): second interim analysis from a double-blind, randomised, placebo-controlled, phase 3 trial.
    Lu S; Wu L; Jian H; Cheng Y; Wang Q; Fang J; Wang Z; Hu Y; Han L; Sun M; Miao L; Ding C; Cui J; Wang K; Li B; Li X; Ye F; Liu A; Pan Y; Cang S; Zhou H; Sun X; Shen Y; Wang S; Zhang W; He Y
    Lancet Respir Med; 2023 Jul; 11(7):624-636. PubMed ID: 37156249
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial.
    West H; McCleod M; Hussein M; Morabito A; Rittmeyer A; Conter HJ; Kopp HG; Daniel D; McCune S; Mekhail T; Zer A; Reinmuth N; Sadiq A; Sandler A; Lin W; Ochi Lohmann T; Archer V; Wang L; Kowanetz M; Cappuzzo F
    Lancet Oncol; 2019 Jul; 20(7):924-937. PubMed ID: 31122901
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial.
    Petrylak DP; de Wit R; Chi KN; Drakaki A; Sternberg CN; Nishiyama H; Castellano D; Hussain SA; Fléchon A; Bamias A; Yu EY; van der Heijden MS; Matsubara N; Alekseev B; Necchi A; Géczi L; Ou YC; Coskun HS; Su WP; Bedke J; Gakis G; Percent IJ; Lee JL; Tucci M; Semenov A; Laestadius F; Peer A; Tortora G; Safina S; Garcia Del Muro X; Rodriguez-Vida A; Cicin I; Harputluoglu H; Tagawa ST; Vaishampayan U; Aragon-Ching JB; Hamid O; Liepa AM; Wijayawardana S; Russo F; Walgren RA; Zimmermann AH; Hozak RR; Bell-McGuinn KM; Powles T;
    Lancet Oncol; 2020 Jan; 21(1):105-120. PubMed ID: 31753727
    [TBL] [Abstract][Full Text] [Related]  

  • 34. SELECT-2: a phase II, double-blind, randomized, placebo-controlled study to assess the efficacy of selumetinib plus docetaxel as a second-line treatment of patients with advanced or metastatic non-small-cell lung cancer.
    Soria JC; Fülöp A; Maciel C; Fischer JR; Girotto G; Lago S; Smit E; Ostoros G; Eberhardt WEE; Lishkovska P; Lovick S; Mariani G; McKeown A; Kilgour E; Smith P; Bowen K; Kohlmann A; Carlile DJ; Jänne PA
    Ann Oncol; 2017 Dec; 28(12):3028-3036. PubMed ID: 29045535
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study.
    Zhong WZ; Wang Q; Mao WM; Xu ST; Wu L; Shen Y; Liu YY; Chen C; Cheng Y; Xu L; Wang J; Fei K; Li XF; Li J; Huang C; Liu ZD; Xu S; Chen KN; Xu SD; Liu LX; Yu P; Wang BH; Ma HT; Yan HH; Yang XN; Zhou Q; Wu YL;
    Lancet Oncol; 2018 Jan; 19(1):139-148. PubMed ID: 29174310
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Vandetanib versus gefitinib in patients with advanced non-small-cell lung cancer: results from a two-part, double-blind, randomized phase ii study.
    Natale RB; Bodkin D; Govindan R; Sleckman BG; Rizvi NA; Capó A; Germonpré P; Eberhardt WE; Stockman PK; Kennedy SJ; Ranson M
    J Clin Oncol; 2009 May; 27(15):2523-9. PubMed ID: 19332730
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study.
    Ciuleanu T; Stelmakh L; Cicenas S; Miliauskas S; Grigorescu AC; Hillenbach C; Johannsdottir HK; Klughammer B; Gonzalez EE
    Lancet Oncol; 2012 Mar; 13(3):300-8. PubMed ID: 22277837
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study.
    Cappuzzo F; Ciuleanu T; Stelmakh L; Cicenas S; Szczésna A; Juhász E; Esteban E; Molinier O; Brugger W; Melezínek I; Klingelschmitt G; Klughammer B; Giaccone G;
    Lancet Oncol; 2010 Jun; 11(6):521-9. PubMed ID: 20493771
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Nakagawa K; Garon EB; Seto T; Nishio M; Ponce Aix S; Paz-Ares L; Chiu CH; Park K; Novello S; Nadal E; Imamura F; Yoh K; Shih JY; Au KH; Moro-Sibilot D; Enatsu S; Zimmermann A; Frimodt-Moller B; Visseren-Grul C; Reck M;
    Lancet Oncol; 2019 Dec; 20(12):1655-1669. PubMed ID: 31591063
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial.
    Thatcher N; Hirsch FR; Luft AV; Szczesna A; Ciuleanu TE; Dediu M; Ramlau R; Galiulin RK; Bálint B; Losonczy G; Kazarnowicz A; Park K; Schumann C; Reck M; Depenbrock H; Nanda S; Kruljac-Letunic A; Kurek R; Paz-Ares L; Socinski MA;
    Lancet Oncol; 2015 Jul; 16(7):763-74. PubMed ID: 26045340
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.